TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34489309

Group type: EXPERIMENTAL
Intervention: First-line treatment with RAS/BRAF mutation analysis
Number of subjects: 171

Group type: COMPARATOR
Intervention: Patients with plasma RAS/BRAF clearance
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Patients who gained new RAS/BRAF mutations
Number of subjects: 171
Study: 34489348

Group type: EXPERIMENTAL
Intervention: Community neurologists' experiences during the COVID-19 pandemic
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Impact of the COVID-19 pandemic on care provision
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Efforts to improve care delivery
Number of subjects: 20
Study: 34489356

Group type: EXPERIMENTAL
Intervention: Very high/high human development index country settings
Number of subjects: 1100

Group type: COMPARATOR
Intervention: Medium/low human development index country settings
Number of subjects: 1100
Study: 34489388

Group type: EXPERIMENTAL
Intervention: Opioid medications
Number of subjects: 248
Study: 34489682

Group type: EXPERIMENTAL
Intervention: Serum proBDNF
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mature BDNF
Number of subjects: 0
Study: 34489850

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 34490173

Group type: EXPERIMENTAL
Intervention: Diabetes self-management intervention
Number of subjects: 0
Study: 34490414

Group type: EXPERIMENTAL
Intervention: B cell depleting therapies (BCDTs)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Vaccination
Number of subjects: 11
Study: 34490424

Group type: EXPERIMENTAL
Intervention: Slip-perturbation training (St)
Number of subjects: 169

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 169
Study: 34490590

Group type: EXPERIMENTAL
Intervention: CYP2C19 genotype-guided strategy
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Standard treatment with ticagrelor or prasugrel
Number of subjects: 1000
Study: 34490604

Group type: EXPERIMENTAL
Intervention: Sodium restriction (2 g of sodium/day)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Sodium restriction (2 g of sodium/day) with sodium intake < 2500 mg/day
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control (3 g of sodium/day)
Number of subjects: 70
Study: 34491103

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 34491326

Group type: EXPERIMENTAL
Intervention: Higher dietary glycaemic load (GL)
Number of subjects: 103020

Group type: EXPERIMENTAL
Intervention: Higher contribution of medium/high-GI foods to energy intake
Number of subjects: 103020

Group type: EXPERIMENTAL
Intervention: Higher contribution of low-GI food/beverages to energy intake
Number of subjects: 103020
Study: 34491406

Group type: EXPERIMENTAL
Intervention: OB (Optic neuritis) present
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Infratentorial lesions present
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Spinal cord lesions present
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Presence of two risk factors (OB, infratentorial or spinal cord lesions)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Presence of three risk factors (OB, infratentorial and spinal cord lesions)
Number of subjects: 88
Study: 34491526

Group type: EXPERIMENTAL
Intervention: CogMed Working Memory Training (CWMT)
Number of subjects: 20
Study: 34491661

Group type: EXPERIMENTAL
Intervention: Intensive treatment (systolic blood-pressure target of 110 to less than 130 mm Hg)
Number of subjects: 8511

Group type: COMPARATOR
Intervention: Standard treatment (systolic blood-pressure target of 130 to less than 150 mm Hg)
Number of subjects: 8511

Group type: EXPERIMENTAL
Intervention: Intensive treatment
Number of subjects: 8511
Study: 34491815

Group type: EXPERIMENTAL
Intervention: Cabozantinib 40 mg once a day plus atezolizumab 1,200 mg intravenously every 3 weeks
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Cabozantinib 60 mg once a day plus atezolizumab 1,200 mg intravenously every 3 weeks
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Cabozantinib (dosage not specified) plus atezolizumab 1,200 mg intravenously every 3 weeks in non-clear cell RCC
Number of subjects: 102
Study: 34491825

Group type: EXPERIMENTAL
Intervention: Novel CGM-Informed Bolus Calculator with Automatic Glucose Trend Adjustment
Number of subjects: 0
Study: 34491885

Group type: EXPERIMENTAL
Intervention: Prolonged prone positioning
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 0
Study: 34492112

Group type: EXPERIMENTAL
Intervention: Retinal arteriolar fractal dimension (second tertile)
Number of subjects: 652

Group type: EXPERIMENTAL
Intervention: Retinal arteriolar fractal dimension (lowest tertile)
Number of subjects: 652

Group type: EXPERIMENTAL
Intervention: Retinal venular branching angle (highest tertile)
Number of subjects: 652
Study: 34492682

Group type: EXPERIMENTAL
Intervention: Dasatinib-dexamethasone induction followed by RIC allogeneic HCT
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Dasatinib-dexamethasone induction followed by autologous HCT
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Dasatinib-dexamethasone induction followed by chemotherapy
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Dasatinib-dexamethasone induction with CNS prophylaxis
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Dasatinib-dexamethasone induction
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: p190 isoform
Number of subjects: 65

Group type: COMPARATOR
Intervention: Allogeneic HCT
Number of subjects: 65

Group type: COMPARATOR
Intervention: Autologous HCT
Number of subjects: 65

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 65
Study: 34492703

Group type: EXPERIMENTAL
Intervention: CD19CAR T-cell therapy
Number of subjects: 5
Study: 34493347

Group type: EXPERIMENTAL
Intervention: Single serum urate (sUA) measurements
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Initial sUA < 6.0 mg/dL
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Initial sUA between 6.0-6.8 mg/dL
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Participants initially hyperuricemic (n = 13)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Mean coefficient of variation for sUA
Number of subjects: 85
Study: 34493500

Group type: EXPERIMENTAL
Intervention: GIB-positive group (n=282)
Number of subjects: 23794

Group type: COMPARATOR
Intervention: GIB-negative group (n=23,512)
Number of subjects: 23794
Study: 34493509

Group type: EXPERIMENTAL
Intervention: Ultrasound (US) evaluation of fetal head position, descent, and rotation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sonopartogram
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: US labour monitoring
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Comparison with classic and recent partogram models
Number of subjects: 0
Study: 34493532

Group type: EXPERIMENTAL
Intervention: Low annual household income (<¥10,000, ¥10,000-19,999)
Number of subjects: 3975

Group type: COMPARATOR
Intervention: Annual household income ≥¥20,000
Number of subjects: 3975
Study: 34493823

Group type: EXPERIMENTAL
Intervention: VISTA positivity in immune cells
Number of subjects: 839

Group type: EXPERIMENTAL
Intervention: VISTA positivity in tumor cells
Number of subjects: 839

Group type: EXPERIMENTAL
Intervention: VISTA expression
Number of subjects: 839
Study: 34494088

Group type: EXPERIMENTAL
Intervention: Lactulose (20 g)
Number of subjects: 38

Group type: COMPARATOR
Intervention: N/A (Control group: Lean youth)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: N/A (DNL measurement)
Number of subjects: 38
Study: 34494149

Group type: EXPERIMENTAL
Intervention: Near-infrared fluorescence imaging with indocyanine green (ICG)
Number of subjects: 84
Study: 34494292

Group type: EXPERIMENTAL
Intervention: Self-reported gingival bleeding on brushing (GBoB)
Number of subjects: 408

Group type: COMPARATOR
Intervention: Absence of self-reported GBoB and low levels of haemoglobin
Number of subjects: 408
Study: 34494363

Group type: EXPERIMENTAL
Intervention: Nuts (specific types not mentioned)
Number of subjects: 0
Study: 34494545

Group type: EXPERIMENTAL
Intervention: Long telomere length (TL)
Number of subjects: 713

Group type: COMPARATOR
Intervention: Other outcomes
Number of subjects: 713
Study: 34494969

Group type: EXPERIMENTAL
Intervention: MoB educational intervention (combined in-person and web-based)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 80
Study: 34495306

Group type: EXPERIMENTAL
Intervention: TAA-Ts (tumor-associated antigen-specific T cells)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: TAA-Ts with nivolumab priming
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: TAA-Ts as adjuvant therapy
Number of subjects: 10

Group type: COMPARATOR
Intervention: Nivolumab priming
Number of subjects: 10
Study: 34495549

Group type: EXPERIMENTAL
Intervention: Integrated disease management (IDM) programmes
Number of subjects: 21086
Study: 34495880

Group type: EXPERIMENTAL
Intervention: SLANT score (risk score model)
Number of subjects: 0
Study: 34496014

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg IV every 3 weeks
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 12
Study: 34496148

Group type: EXPERIMENTAL
Intervention: PrEP delivery with no creatinine testing
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: PrEP delivery with peer on-the-job training
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: PrEP delivery discussed in routine meetings
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: PrEP dispensed in clinic rooms
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: PrEP offered at nonregular hours
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: PrEP education and adherence counselling
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Issuing 2-3 months of pills at a time
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Incorporating PrEP-related topics into routine health talks
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Calling clients with missed PrEP appointments
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Fast-tracking PrEP clients
Number of subjects: 25
Study: 34496250

Group type: EXPERIMENTAL
Intervention: Psychological stress (PS)
Number of subjects: 0
Study: 34496270

Group type: EXPERIMENTAL
Intervention: Facial botulinum toxin injections
Number of subjects: 84

Group type: COMPARATOR
Intervention: Cervical botulinum toxin injections
Number of subjects: 84

Group type: COMPARATOR
Intervention: No injections (control group)
Number of subjects: 84
Study: 34496464

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 34496617

Group type: EXPERIMENTAL
Intervention: Transesophageal echocardiography (TEE)
Number of subjects: 494

Group type: COMPARATOR
Intervention: Transthoracic echocardiography (TTE)
Number of subjects: 494
Study: 34496748

Group type: EXPERIMENTAL
Intervention: Initial shockable cardiac rhythm
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Low base excess at admission
Number of subjects: 50
Study: 34496754

Group type: EXPERIMENTAL
Intervention: Needle insertion angle in group S (spondylolisthesis)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Needle insertion angle in group N (no spondylolisthesis)
Number of subjects: 40
Study: 34496807

Group type: EXPERIMENTAL
Intervention: Segmental reconstruction of the defect with fresh-frozen humeral head osteochondral allografts
Number of subjects: 12
Study: 34496904

Group type: EXPERIMENTAL
Intervention: Males
Number of subjects: 200

Group type: COMPARATOR
Intervention: Females
Number of subjects: 200

Group type: COMPARATOR
Intervention: TKA implants
Number of subjects: 200
Study: 34497076

Group type: EXPERIMENTAL
Intervention: Adolescents with type 1 diabetes (T1D)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Adolescents with T1D
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Adolescents with T1D and Healthy controls
Number of subjects: 200
Study: 34497087

Group type: EXPERIMENTAL
Intervention: ICU discharge assessment
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: ICU discharge, 3 months and 6 months assessments
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: 6 months after ICU discharge
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: 3 months after discharge
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: During the pandemic
Number of subjects: 450
Study: 34497426

Group type: EXPERIMENTAL
Intervention: Pulmonary function tests, serum biomarkers, chest radiography, and chest CT performed at outpatient visits.
Number of subjects: 313

Group type: COMPARATOR
Intervention: Severe COVID-19 pneumonia patients
Number of subjects: 313
Study: 34497546

Group type: EXPERIMENTAL
Intervention: fMRI Neurofeedback-supported cognitive reappraisal training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 34497783

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 34498074

Group type: EXPERIMENTAL
Intervention: Early adenotonsillectomy (eAT)
Number of subjects: 404

Group type: COMPARATOR
Intervention: Watchful waiting with supportive care (WWSC)
Number of subjects: 404
Study: 34498344

Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 95
Study: 34499038

Group type: EXPERIMENTAL
Intervention: Digital rehabilitation therapy using a biofeedback device provided by SWORD Health, performed independently at home.
Number of subjects: 93
Study: 34499161

Group type: EXPERIMENTAL
Intervention: Brief-BESTest after 12-week pulmonary rehabilitation (PR) program including balance training
Number of subjects: 71

Group type: COMPARATOR
Intervention: 6-Minute Walk Test (6-MWT)
Number of subjects: 71

Group type: COMPARATOR
Intervention: modified British Medical Research Council (mMRC) dyspnea scale
Number of subjects: 71
Study: 34499222

Group type: EXPERIMENTAL
Intervention: GSTM1/GSTT1 double null genotype
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: BU-induced cell death studies in GSTs-null LCLs and THP1 leukemia cell lines
Number of subjects: 86
Study: 34499238

Group type: EXPERIMENTAL
Intervention: Turkish version of QUALEFFO-31
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: QUALEFFO-31
Number of subjects: 111

Group type: COMPARATOR
Intervention: QUALEFFO-31 and SF-36
Number of subjects: 111
Study: 34499349

Group type: EXPERIMENTAL
Intervention: Ibuprofen 300 mg
Number of subjects: 201

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Acetaminophen 1000 mg
Number of subjects: 201
Study: 34499383

Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve implantation (TAVI) with a balloon-expandable transcatheter aortic valve
Number of subjects: 2400

Group type: EXPERIMENTAL
Intervention: Implementation of tailored quality of care (QoC) measures
Number of subjects: 2400
Study: 34499416

Group type: EXPERIMENTAL
Intervention: Merestinib 80 mg orally QD during a 28-day cycle
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Merestinib 120 mg orally QD during a 28-day cycle
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Merestinib 80 mg orally QD with cisplatin 25 mg/m2
Number of subjects: 0
Study: 34499613

Group type: EXPERIMENTAL
Intervention: Web-based cognitive behavioral therapy, mindfulness meditation, and yoga (CBT-MY)
Number of subjects: 22
Study: 34499720

Group type: EXPERIMENTAL
Intervention: 2 g cefazolin IV infusion
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 1 g cefazolin IV infusion (administered if delivery delayed >8 h)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Standard pre-delivery maternal cefazolin dosing
Number of subjects: 24
Study: 34499723

Group type: EXPERIMENTAL
Intervention: SMART Pass (SP) filter enabled
Number of subjects: 126

Group type: COMPARATOR
Intervention: Conventional automated screening tool (AST) without SP filter
Number of subjects: 126
Study: 34499863

Group type: EXPERIMENTAL
Intervention: TST (Tuberculin Skin Test)
Number of subjects: 21846

Group type: EXPERIMENTAL
Intervention: QuantiFERON
Number of subjects: 21846

Group type: EXPERIMENTAL
Intervention: T-SPOT.TB
Number of subjects: 21846

Group type: EXPERIMENTAL
Intervention: TST
Number of subjects: 21846

Group type: EXPERIMENTAL
Intervention: IFN-γ release assay
Number of subjects: 21846
Study: 34499875

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 34500427

Group type: EXPERIMENTAL
Intervention: Atlas-based disconnectome computation pipeline
Number of subjects: 0
Study: 34500472

Group type: EXPERIMENTAL
Intervention: Ibrutinib + Nivolumab
Number of subjects: 67
Study: 34503290

Group type: EXPERIMENTAL
Intervention: BNT162b2 vaccine (two doses)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Healthy matched controls (vaccinated with BNT162b2)
Number of subjects: 132
Study: 34503455

Group type: EXPERIMENTAL
Intervention: Propofol continuous infusion with a stepwise increase of 1 μg/mL in effect-site concentration (C)
Number of subjects: 30
Study: 34503520

Group type: EXPERIMENTAL
Intervention: Questionnaires (CAT 1 & 7, SGRQ 8 & 12 sub-item 3)
Number of subjects: 436

Group type: EXPERIMENTAL
Intervention: Spirometric measures (FEV)
Number of subjects: 436
Study: 34503735

Group type: EXPERIMENTAL
Intervention: TRK inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HER2-targeted therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immunotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Biologically rational clinical trials
Number of subjects: 0
Study: 34503738

Group type: EXPERIMENTAL
Intervention: Coronary stent intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 34503739

Group type: EXPERIMENTAL
Intervention: Major residual FFR gradient defined by dFFR(t)/dt (≥0.035)
Number of subjects: 492

Group type: COMPARATOR
Intervention: Conventional visual assessment of the major residual FFR gradient
Number of subjects: 492

Group type: COMPARATOR
Intervention: Inclusion of major residual FFR gradient in clinical prediction model
Number of subjects: 492

Group type: EXPERIMENTAL
Intervention: Presence of major residual FFR gradient
Number of subjects: 492
Study: 34503740

Group type: EXPERIMENTAL
Intervention: FFR after stenting
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 34503741

Group type: EXPERIMENTAL
Intervention: Lesions with FFR ≤0.8 but CFR ≥2.0
Number of subjects: 455

Group type: COMPARATOR
Intervention: Lesions with FFR >0.8 and CFR ≥2.0
Number of subjects: 455
Study: 34503957

Group type: EXPERIMENTAL
Intervention: Glucagonlike peptide-1 receptor (GLP1R) imaging using PET radioligand
Number of subjects: 0
Study: 34503986

Group type: EXPERIMENTAL
Intervention: Methionine supplementation
Number of subjects: 4
Study: 34504017

Group type: EXPERIMENTAL
Intervention: Transcranial microbubble-enhanced focused ultrasound (MB-FUS)
Number of subjects: 0
Study: 34504056

Group type: EXPERIMENTAL
Intervention: Reduced synthesis of cholesterol, reduced amounts of high-density lipoprotein cholesterol (HDL), apolipoprotein A1 (ApoA1), and apolipoprotein B (ApoB).
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Levels less than the fifth centile of HDL or ApoA1 or ApoA1 + ApoB.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hypocholesterolemic subjects.
Number of subjects: 0
Study: 34504096

Group type: EXPERIMENTAL
Intervention: Weekly paclitaxel and bevacizumab chemotherapy
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: CTCs and ctDNA levels at baseline and after four weeks of treatment
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: CTC count at four weeks (≥5CTC/7.5 mL)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: ctDNA variant allele frequency (VAF) at baseline (per 10% increase)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: KMT2C/MLL3 variants detected in ctDNA
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: GATA3 alterations
Number of subjects: 198
Study: 34504469

Group type: EXPERIMENTAL
Intervention: Stent Retriever Thrombectomy for Anterior Circulation Ischemic Stroke
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stent Retriever Thrombectomy for Posterior Circulation Ischemic Stroke
Number of subjects: 0
Study: 34504796

Group type: EXPERIMENTAL
Intervention: Dabrafenib (150 mg twice daily) plus Trametinib (2 mg once daily)
Number of subjects: 60
Study: 34505132

Group type: EXPERIMENTAL
Intervention: Tuberculosis Preventive Therapy
Number of subjects: 0
Study: 34505172

Group type: EXPERIMENTAL
Intervention: Regular dose (RD) protocol, volumetric CT dose index (CTDIvol) 3.04 mGy, 64-slice unit
Number of subjects: 49

Group type: COMPARATOR
Intervention: Ultra-low dose (ULD) protocol, median CTDIvol 0.38 mGy, dual-source unit
Number of subjects: 49
Study: 34505831

Group type: EXPERIMENTAL
Intervention: AI4DM intervention (telecoaching, diabetes educational content, technology access)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Attention control group
Number of subjects: 90
Study: 34505835

Group type: EXPERIMENTAL
Intervention: Telehealth platform with health coaching (AI4DM)
Number of subjects: 0
Study: 34505833

Group type: EXPERIMENTAL
Intervention: Group-based substance use intervention for girls and young women
Number of subjects: 114
Study: 34506511

Group type: EXPERIMENTAL
Intervention: Sleep apnea
Number of subjects: 1204

Group type: COMPARATOR
Intervention: No sleep apnea (Control)
Number of subjects: 1204
Study: 34506666

Group type: EXPERIMENTAL
Intervention: Icatibant treatment
Number of subjects: 607
Study: 34506875

Group type: EXPERIMENTAL
Intervention: Fluid bolus of 500 ml plasma-lyte A
Number of subjects: 52
Study: 34506898

Group type: EXPERIMENTAL
Intervention: Stellarex drug-coated balloon (DCB)
Number of subjects: 589

Group type: COMPARATOR
Intervention: Percutaneous transluminal angioplasty (PTA)
Number of subjects: 589
Study: 34506988

Group type: EXPERIMENTAL
Intervention: Total egg consumption (>1 egg/d)
Number of subjects: 8241

Group type: EXPERIMENTAL
Intervention: Fried egg consumption (>1/2 egg/d)
Number of subjects: 8241

Group type: EXPERIMENTAL
Intervention: Total dietary intake and egg-sourced cholesterol intake
Number of subjects: 8241
Study: 34507560

Group type: EXPERIMENTAL
Intervention: Surgical treatment with a stoma
Number of subjects: 376

Group type: EXPERIMENTAL
Intervention: Smoking habits
Number of subjects: 376

Group type: EXPERIMENTAL
Intervention: Higher body mass index
Number of subjects: 376

Group type: EXPERIMENTAL
Intervention: American Society of Anesthesiologists physical status 3 and 4
Number of subjects: 376

Group type: COMPARATOR
Intervention: No stoma treatment
Number of subjects: 376
Study: 34507574

Group type: EXPERIMENTAL
Intervention: Transdermal fentanyl 12 mcg/h
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Sustained-release morphine 10 mg b.i.d.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60